- Type / Class
- Equity / COM
- Shares outstanding
- 258,506,508
- Total 13F shares
- 111,244,473
- Share change
- -14,896,172
- Total reported value
- $160,207,390
- Put/Call ratio
- 394%
- Price per share
- $1.44
- Number of holders
- 183
- Value change
- -$24,300,645
- Number of buys
- 76
- Number of sells
- 84
Quarterly Holders Quick Answers
What is CUSIP 29664W105?
CUSIP 29664W105 identifies ESPR - Esperion Therapeutics, Inc. - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 29664W105:
Top shareholders of ESPR - Esperion Therapeutics, Inc. - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| WASATCH ADVISORS LP |
13F
|
Company |
9.5%
|
24,482,258
|
$53,860,968 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
5.5%
|
14,235,423
|
$31,317,931 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.5%
|
11,715,748
|
$25,774,646 | — | 31 Dec 2024 | |
| Bellevue Group AG |
13F
|
Company |
3.8%
|
9,944,064
|
$21,876,941 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
2.4%
|
6,309,377
|
$13,880,631 | — | 31 Dec 2024 | |
| Two Seas Capital LP |
13F
|
Company |
2.4%
|
6,230,871
|
$13,707,916 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
1.7%
|
4,504,234
|
$9,909,315 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
4,339,948
|
$9,549,786 | — | 31 Dec 2024 | |
| BB BIOTECH AG |
13D/G
|
— |
4.9%
|
9,694,064
|
$8,821,598 | -$227,500 | 04 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.4%
|
3,616,200
|
$7,955,640 | — | 31 Dec 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.4%
|
3,540,361
|
$7,788,794 | — | 31 Dec 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
1.2%
|
3,119,253
|
$6,862,356 | — | 31 Dec 2024 | |
| Indaba Capital Management, L.P. |
13F
|
Company |
1.2%
|
3,000,000
|
$6,600,000 | — | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.1%
|
2,753,260
|
$6,057,172 | — | 31 Dec 2024 | |
| BIOTECH TARGET N V |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,477,964
|
$5,575,065 | — | 24 May 2021 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.95%
|
2,454,216
|
$5,399,275 | — | 31 Dec 2024 | |
| Rhenman & Partners Asset Management AB |
13F
|
Company |
0.74%
|
1,915,000
|
$4,213,000 | — | 31 Dec 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.68%
|
1,754,632
|
$3,860,190 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.63%
|
1,629,980
|
$3,585,956 | — | 31 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.6%
|
1,540,084
|
$3,388,184 | — | 31 Dec 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.58%
|
1,503,746
|
$3,308,241 | — | 31 Dec 2024 | |
| CenterBook Partners LP |
13F
|
Company |
0.51%
|
1,306,259
|
$2,873,770 | — | 31 Dec 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.36%
|
932,008
|
$2,050,418 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0.34%
|
876,942
|
$1,929,272 | — | 31 Dec 2024 | |
| PLATINUM INVESTMENT MANAGEMENT LTD |
13F
|
Company |
0.32%
|
840,052
|
$1,848,114 | — | 31 Dec 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.32%
|
829,885
|
$1,825,747 | — | 31 Dec 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.28%
|
728,232
|
$1,602,110 | — | 31 Dec 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.22%
|
578,800
|
$1,273,360 | — | 31 Dec 2024 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.22%
|
560,545
|
$1,233,000 | — | 31 Dec 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.22%
|
560,276
|
$1,232,607 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.21%
|
554,216
|
$1,219,275 | — | 31 Dec 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.17%
|
427,532
|
$940,572 | — | 31 Dec 2024 | |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO |
13F
|
Company |
0.14%
|
367,373
|
$808,221 | — | 31 Dec 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.14%
|
359,235
|
$790,317 | — | 31 Dec 2024 | |
| Diametric Capital, LP |
13F
|
Company |
0.14%
|
354,010
|
$778,822 | — | 31 Dec 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.13%
|
339,032
|
$745,870 | — | 31 Dec 2024 | |
| Joanne M. Foody |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
472,862
mixed-class rows
|
$709,168 | — | 17 Jul 2024 | |
| Marex Group plc |
13F
|
Company |
0.11%
|
275,000
|
$605,000 | — | 31 Dec 2024 | |
| Headlands Technologies LLC |
13F
|
Company |
0.1%
|
255,066
|
$561,145 | — | 31 Dec 2024 | |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.1%
|
254,265
|
$559,383 | — | 31 Dec 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.1%
|
251,592
|
$553,502 | — | 31 Dec 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.1%
|
246,914
|
$543,207 | — | 31 Dec 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.09%
|
228,730
|
$503,206 | — | 31 Dec 2024 | |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP |
13F
|
Company |
0.09%
|
222,482
|
$489,460 | — | 31 Dec 2024 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.08%
|
197,919
|
$435,421 | — | 31 Dec 2024 | |
| NJ State Employees Deferred Compensation Plan |
13F
|
Company |
0.08%
|
195,125
|
$429,275 | — | 31 Dec 2024 | |
| Graham Capital Management, L.P. |
13F
|
Company |
0.07%
|
192,415
|
$423,313 | — | 31 Dec 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.07%
|
192,123
|
$422,671 | — | 31 Dec 2024 | |
| Sigma Planning Corp |
13F
|
Company |
0.07%
|
190,441
|
$418,970 | — | 31 Dec 2024 | |
| Pentwater Capital Management LP |
13F
|
Company |
0.07%
|
181,290
|
$398,838 | — | 31 Dec 2024 |
Institutional Holders of Esperion Therapeutics, Inc. - COM (ESPR) as of Q1 2025
As of 31 Mar 2025,
Esperion Therapeutics, Inc. - COM (ESPR) was held by
183 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
111,244,473 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, WASATCH ADVISORS LP, Bellevue Group AG, Two Seas Capital LP, MORGAN STANLEY, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, MARSHALL WACE, LLP, and Nuveen, LLC.
This page lists
184
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
188
Q1 2025 holders
183
Holder diff
-5
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.